[Translation] A single-center, single-dose, open-label, randomized, two-period crossover bioequivalence study of cefprozil dispersible tablets in healthy volunteers under fasting and fed conditions
主要目的:考察由上海美优制药有限公司生产的头孢丙烯分散片(受试制剂,规格:0.25 g/片)和原研Lupin Limited生产的头孢丙烯片(参比制剂,规格:250 mg/片,英文名:Cefprozil Tablets USP)在空腹条件下单剂量口服250 mg及高脂高热量餐后条件下单剂量口服250 mg在中国健康人体的药代动力学特征,评价两种制剂的生物等效性。次要目的:观察受试制剂和参比制剂在健康受试者中的安全性。
[Translation] Primary objective: To investigate the pharmacokinetic characteristics of Cefprozil Dispersible Tablets (test preparation, specification: 0.25 g/tablet) produced by Shanghai Meiyu Pharmaceutical Co., Ltd. and Cefprozil Tablets (reference preparation, specification: 250 mg/tablet, English name: Cefprozil Tablets USP) produced by Lupin Limited (reference preparation, specification: 250 mg/tablet) in healthy Chinese subjects after a single oral dose of 250 mg under fasting conditions and after a high-fat, high-calorie meal, and to evaluate the bioequivalence of the two preparations. Secondary objective: To observe the safety of the test preparation and the reference preparation in healthy subjects.